Seminars in Oncology Nursing
Volume 25, Issue 1 , Pages 48-60 , February 2009

Gastrointestinal Stromal Tumors and Neuroendocrine Tumors

References 

  1. American Cancer Society. Learn about cancer, gastrointestinal stromal tumors. Available at: www.cancer.org (accessed April 21, 2008).
  2. Badalamenti G, Rodolico V, Fulfaro F, et al. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol. 2007;18(Suppl 6):vi136–vi140
  3. Gutierrez JC, De Oliveira LO, Perez EA, et al. Optimizing diagnosis, staging, and management of gastrointestinal stromal tumors. J Am Coll Surg. 2007;205:479–491
  4. Kindblom LG, Meis-Kindblom J, Bumming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell (GIST): a population-based study of 600 cases. [abstr 5770] Ann Oncol. 2002;13:157
  5. Fletcher C, Berman J, Corless G, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–465
  6. Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases. Cancer. 1977;39:255–262
  7. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710
  8. Online Mendalian Inheritance in Man. Gastrointestinal Stromal Tumor; GIST. Available at: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=606764 (accessed April 21, 2008).
  9. von Mehren M. New approaches to gastrointestinal stromal tumors. Oncology. 2006;9:97–100
  10. National Comprehensive Cancer Network. NCCN clinical practice guidelines in sarcoma, v.1.2008. 2008. Available at: http://www.nccn.org (accessed April, 21, 2008).
  11. Miettinen M, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477–489
  12. Griffin JM, Amand MS, Dimitri GD. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. Clin J Oncol Nurs. 2005;9:161–169
  13. Raut CP, Ashley SW. How I do it: surgical management of gastrointestinal stromal tumors. J Gastrointest Surg. 2008;12:1592–1599
  14. Pfisters PWT, Bramwell VHC, Rubin BP, et al. Sarcomas of soft tissue. In:  Abeloff MD,  Armitage JO,  Niederhuber JE,  Kastan MB,  McKenna WG editor. Clinical oncology. Philadelphia, PA: Elsevier; 2004;p. 2608–2609
  15. D'Amato G, Steinert GM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005;12:44–56
  16. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  17. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet. 2004;364:1127–1134
  18. Rankin C, von Mehren M, Blanke C, et al. Dose effect of imatinib in patients with metastatic GIST – phase III sarcoma group study S0033. [abstr 9005] J Clin Oncol 2004 ASCO Annual Meeting Proceedings. 2004;22(July 15 suppl):14s
  19. Blanke C, Rankin C, Demetri GD, et al. Randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase; S0033. J Clin Oncol. 2008;26:626–632
  20. Blanke C, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-verses higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–625
  21. Novartis Oncology . Imatinib® (imatinib mesylate). [Package insert] East Hanover, NJ: Novartis Oncology; 2003;
  22. Pfizer Oncology . Sutent (sunitinib malate). [Package insert] New York, NY: Pfizer Oncology; 2006;
  23. Deninger NW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21:1637–1647
  24. DeMatteo R, Owzar K, Maki R, et al. (2007). Adjuvant imatinib mesylate increases recurrence-free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumors (GIST): North American intergroup phase III trial ACOSOG Z9001 [abstr 10079]. American Society of Clinical Oncology 2007 Annual Meeting. Available at: http://www.asco.org/(accessed May 1, 2008).
  25. Demetri GD, van Oosteram AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. Lancet. 2006;368:1329–1338
  26. Wiebe L, Kasza KE, Maki RG, et al. Activity of sorafenib in patients with imatinib and sunitinib-resistant gastrointestinal stromal tumors: a phase II trial of the University of Chicago Phase II consortium [abstr 10502]. J Clin Oncol 2008 ASCO Annual Meeting. 26 (May 20 suppl). Available at: http://www.asco.org/ (accessed July 18, 2008).
  27. Birner A. Safe administration of oral chemotherapy. Clin J Oncol Nurs. 2003;7:158–162
  28. Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs. 2003;7(Suppl 7):21–24
  29. McGraw C, Drennan V. Self-administration of medicine and older people. Nurs Standard. 2001;15:33–36
  30. van Eijken M, Tsang S, Wensing M, et al. Interventions to improve medication compliance in older persons living in the community: a systematic review of the literature. Drugs Aging. 2003;20:229–240
  31. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959
  32. Creutzfeldt W, Stockman F. Carcinoids and carcinoid syndrome. Am J Med. 1987;82:4–16
  33. Williams ED, Sandler M. The classification of carcinoid tumors. Lancet. 1963;1:238–239
  34. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci. 2004;1014:13–27
  35. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) data base, 1973-2004. Available at: http://seer.cancer.gov/ (accessed June, 7, 2008).
  36. Hemminki K, Li X. Incidence, trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92:2204–2210
  37. Jensen RT, Doherty GM. Carcinoid tumors and carcinoid syndrome. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles & practice of oncology. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001;p. 1813–1833
  38. Zikusoka MN, Kidd M, Eick G, et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer. 2005;104:2292–2309
  39. Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol. 2008;103:729–732
  40. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–1751
  41. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer. 2002;37:127–135
  42. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293–2301
  43. Tomassetti P, Migliori M, Lalli S, et al. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol. 2001;12(Suppl 2):S95–S99
  44. Vinik AI, O'Dorisio TM, Woltering EA, et al. Neuroendocrine tumors: a comprehensive guide to diagnosis and management. Available at: http://www.carcinoid.org/medpro/docs/WolteringVinikISIbook1.pdf (accessed July 10, 2008).
  45. deVries H, Wijffels RT, Willemse PH, et al. Abdominal angina in patients with a midgut carcinoid, a sign of severe pathology. World J Surg. 2005;29:1139–1142
  46. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid; presentation, diagnosis and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119:1647–1651
  47. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340:858–868
  48. Oberg K. Carcinoid tumors. In:  Foley JF,  Vose JM,  Armitage JO editor. Current therapy in cancer. 2nd ed. Philadelphia, PA: WB Saunders; 1999;p. 230–236
  49. Klöppel G, Rindi G, Anlauf M, et al. Site-specific biology and pathology of Gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(Suppl 1):S9–S27
  50. Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumors with [111 In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Q J Med. 1998;91:295–301
  51. Anderson AS, Krauss D, Lang R. Cardiovascular complications of malignant carcinoid disease. Am Heart J. 1997;134:693–702
  52. Borch K, Ahren B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242:62–73
  53. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–944
  54. Plockinger U, Wiedenmann B. Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(Suppl 1):S71–S80
  55. Oberg K, Caplin M, Delle Fave G, et al. Consensus report on the use of somatostatin analogues for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;6:966–973

PII: S0749-2081(08)00075-2

doi: 10.1016/j.soncn.2008.10.004

Seminars in Oncology Nursing
Volume 25, Issue 1 , Pages 48-60 , February 2009

Article Tools